A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zhang, Hao ^a   Berel, Dror ^a   Wang, Yanping ^a   Li, Ping ^a   Bhowmick, Neil A ^a   Figlin, Robert A ^a   Kim, Hyung L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; KU 0063794; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; S6 KINASE; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MORPHOLINES; MULTIPROTEIN COMPLEXES; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEIN V-AKT; PHOSPHOPROTEINS; PYRIMIDINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84872781534     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054918     Document Type: Article

References (37)

1. Rini BI, Campbell SC, Escudier B, (2009) Renal cell carcinoma. Lancet 373: 1119-1132.
2. Motzer RJ, Russo P, (2000) Systemic therapy for renal cell carcinoma. J Urol 163: 408-417.
3. Furge KA, MacKeigan JP, Teh BT, (2010) Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol 11: 571-578.
4. Foster KG, Fingar DC, (2010) Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077.
5. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
6. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
7. Sparks CA, Guertin DA, (2010) Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29: 3733-3744.
8. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
9. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256-4265.
10. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
11. Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, et al. (2007) Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25: 3958-3964.
12. Rini BI, Atkins MB, (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000.
13. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70: 288-298.
14. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38.
15. Janes MR, Limon JJ, So L, Chen J, Lim RJ, et al. (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213.
16. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, et al. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421: 29-42.
17. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
18. Creighton CJ, (2007) A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene 26: 4648-4655.
19. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, et al. (2010) Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 5: e10696. Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0010696. Accessed: 21 December 2012.
20. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
21. Mizushima N, Yoshimori T, (2007) How to interpret LC3 immunoblotting. Autophagy 3: 542-545.
22. Glenn ST, Head KL, Teh BT, Gross KW, Kim HL, (2010) Maximizing RNA yield from archival renal tumors and optimizing gene expression analysis. J Biomol Screen 15: 80-85.
23. Glenn ST, Jones CA, Liang P, Kaushik D, Gross KW, et al. (2007) Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. Biotechniques 43: 639-640, 642-633, 647.
24. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, et al. (2007) Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 13: 7401-7406.
25. Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, et al. (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12: 5755-5763.
26. Gordan JD, Simon MC, (2007) Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 17: 71-77.
27. Linehan WM, Srinivasan R, Schmidt LS, (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7: 277-285.
28. Toschi A, Lee E, Gadir N, Ohh M, Foster DA, (2008) Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 283: 34495-34499.
29. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr, (2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: E83.
30. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, et al. (2002) The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255.
31. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, et al. (2010) The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16: 3628-3638.
32. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, et al. (2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10: 1019-1027.
33. Blommaart EF, Luiken JJ, Blommaart PJ, van Woerkom GM, Meijer AJ, (1995) Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem 270: 2320-2326.
34. Neufeld TP, (2010) TOR-dependent control of autophagy: biting the hand that feeds. Curr Opin Cell Biol 22: 157-168.
35. Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, et al. (2012) Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J Biol Chem 287: 9742-9752.
36. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS, (2009) mTOR Mediated Anti-Cancer Drug Discovery. Drug Discov Today Ther Strateg 6: 47-55.
37. Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL, (2011) Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer 104: 643-652.